RecruitingNon Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Sponsor: Phanes Therapeutics
Where it's recruiting
North Carolina
Huntersville
Oklahoma
Oklahoma City
Tennessee
Nashville
Texas
Houston · Webster
Virginia
Fairfax
Source: ClinicalTrials.gov · NCT05431270 · last updated 2026-05-19